Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Viale

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Biomed Research International|August 4, 2017
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy EfficacyGiulia Viale, Dario Trapani, Giuseppe Curigliano
JAMA Oncology|March 29, 2019
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A ReviewAngela Esposito, Giulia Viale, Giuseppe Curigliano
BMC Medicine|May 10, 2019
Recent advances in triple negative breast cancer: the immunotherapy eraAntonio Marra, Giulia Viale, Giuseppe Curigliano
Current Opinion in Oncology|October 9, 2019
Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancerCarmen Criscitiello, Giulia Viale, Giuseppe Curigliano
Current Opinion in Oncology|September 6, 2017
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant settingCarmen Criscitiello, Giulia Viale, Giuseppe Curigliano
Breast (Edinburgh, Scotland)|February 16, 2019
Peptide vaccines in early breast cancerCarmen Criscitiello, Giulia Viale, Giuseppe Curigliano
Cancer Cell|February 11, 2025
From intrinsic to adaptive clusters in breast cancerGiampaolo Bianchini, Giulia Viale, Matteo Dugo
Breast Cancer (Dove Medical Press)|February 13, 2018
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to dateCarmen Criscitiello, Giulia Viale, Giuseppe Curigliano, et al.
Expert Opinion on Investigational Drugs|August 10, 2014
Dinaciclib for the treatment of breast cancerCarmen Criscitiello, Giulia Viale, Angela Esposito, et al.
Expert Review of Clinical Pharmacology|November 24, 2018
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancerAngela Esposito, Giulia Viale, Carmen Criscitiello, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Biomed Research International|August 4, 2017
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy EfficacyGiulia Viale, Dario Trapani, Giuseppe Curigliano
JAMA Oncology|March 29, 2019
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A ReviewAngela Esposito, Giulia Viale, Giuseppe Curigliano
BMC Medicine|May 10, 2019
Recent advances in triple negative breast cancer: the immunotherapy eraAntonio Marra, Giulia Viale, Giuseppe Curigliano
Current Opinion in Oncology|October 9, 2019
Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancerCarmen Criscitiello, Giulia Viale, Giuseppe Curigliano
Current Opinion in Oncology|September 6, 2017
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant settingCarmen Criscitiello, Giulia Viale, Giuseppe Curigliano
Breast (Edinburgh, Scotland)|February 16, 2019
Peptide vaccines in early breast cancerCarmen Criscitiello, Giulia Viale, Giuseppe Curigliano
Cancer Cell|February 11, 2025
From intrinsic to adaptive clusters in breast cancerGiampaolo Bianchini, Giulia Viale, Matteo Dugo
Breast Cancer (Dove Medical Press)|February 13, 2018
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to dateCarmen Criscitiello, Giulia Viale, Giuseppe Curigliano, et al.
Expert Opinion on Investigational Drugs|August 10, 2014
Dinaciclib for the treatment of breast cancerCarmen Criscitiello, Giulia Viale, Angela Esposito, et al.
Expert Review of Clinical Pharmacology|November 24, 2018
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancerAngela Esposito, Giulia Viale, Carmen Criscitiello, et al.
Pageof 5